Gene therapy company AskBio has announced encouraging results from the Phase I trial of gene therapy AB-1002 in participants with congestive heart failure. 

The 12-month data set, revealed in Nature Medicine, confirms that meaningful improvements were recorded across several efficacy assessments and no adverse events were related to AB-1002. 

The gene therapy was evaluated in a first-in-human, non-randomised trial, which included escalating dose cohorts to evaluate the safety and preliminary efficacy of investigational gene therapy AB-1002. Participants were patients with New York Heart Association (NYHA) Class III non-ischaemic heart failure with reduced ejection fraction (HFrEF). 

“We believe there is a critical need to progress innovative therapies that target the root causes of congestive heart failure, so we’re pleased to see these data for AB-1002 published and shared with the scientific community via Nature Medicine, a high-impact peer-reviewed journal,” said Canwen Jiang, Chief Development Officer and Chief Medical Officer at AskBio.  

“We’re eager to further assess the safety and efficacy of AB-1002 in our ongoing Phase II trial, GenePHIT, which is currently enrolling in Canada, Europe, the United Kingdom, and the United States, and look forward to sharing those results once available.” 

The impact of heart failure

It is estimated that 64 million people worldwide are living with heart failure and, despite standard of care, mortality and morbidity remain very high. Heart failure occurs when the heart cannot pump blood efficiently enough to meet the body’s needs, including providing sufficient oxygen to the organs.  

Congestive heart failure results in the slowing of the blood flow out of the heart, which causes the blood returning to the heart through the veins to back up. This can lead to congestion in the body’s tissues, with symptoms including shortness of breath, swelling in the legs and ankles caused by fluid retention, and fatigue. 

AB-1002 will now be assessed in GenePHIT, a Phase II, adaptive, randomised, double-blind, placebo-controlled trial investigating the safety and efficacy of AB-1002 in non-ischaemic heart failure. 

 

Bruno Quinney, Content Team, DDW